Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.
bit.bio has raised $50.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.
bit.bio's investors include ARCH Venture Partners, BlueYard Capital, Foresite Capital, Tencent, ZAKA VC.
bit.bio is headquartered in Cambridge, United Kingdom.
Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.
bit.bio is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"bit.bio — Funding & Investors." VCBacked, January 9, 2026, https://www.vcbacked.co/company/bitbio-cambridge. Accessed October 22, 2026.
VCBacked. (2026). bit.bio — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/bitbio-cambridge
{{cite web |title=bit.bio — Funding & Investors |url=https://www.vcbacked.co/company/bitbio-cambridge |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated